|
" Proceedings of the 3rd international congress on neo-adjuvant chemotherapy. "
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
737937
|
| Doc. No
|
:
|
b557814
|
| Title & Author
|
:
|
Proceedings of the 3rd international congress on neo-adjuvant chemotherapy.
|
| Publication Statement
|
:
|
[Place of publication not identified]: Springer, 2014
|
| ISBN
|
:
|
2817807820
|
|
|
:
|
: 9782817807829
|
| Contents
|
:
|
The first Claude Jacquillat Memorial lecture: Chemotherapy of cancer.- Head and Neck.- Neo-Adjuvant chemotherapy for patients with oral and oro-pharyngeal T3/T4 carcinomas.- Induction chemotherapy with Cisplatin and 5-FU for squamous cell carcinoma of the head and neck. Six year experience at the Nice Cancer Center.- Neo-Adjuvant chemotherapy for organ preservation with high dose continuous infusion of Cisplatin, 5-Flurouracil and Mitoguazone for head and neck cancer: a preliminary report.- Significance of tumour site in assessing survival benefit of Neo-Adjuvant chemotherapy in advanced head and neck cancer: a lack of survival advantage in patients with oral cavity tumours despite achieving a high clinical complete remission rate after local therapy.- Preservation of the larynx following Neo-Adjuvant chemotherapy. A preliminary report.- Selection of radiocurable head and neck cancers by Neo-Adjuvant chemotherapy response.- Neo-Adjuvant chemotherapy with Cisplatin and 5-Fluorouracil, both in continuous 96 hours perfusion, in the multidisciplinary treatment of locally advanced head and neck cancer.- Organ preservation in the treatment of hypopharyngeal squamous cell carcinoma. Preliminary results of a randomized trial.- Regional control after induction chemotherapy for advanced squamous cell carcinoma of the head and neck: a retrospective analysis of 303 patients.- Exclusive chemotherapy in head and neck cancer.- Neo-Adjuvant Cisplatin, 5-Fluorouracil and high-dose Leucovorin for advanced head and neck cancer: response, toxicity, survival and comparison with historical controls.- 5-Fluorouracil modulation in head and neck cancer.- Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer.- Efficacy of concomitant chemoradiotherapy in poor prognosis head and neck cancer.- Radiotherapy (RT) with concomitant Cisplatin (CDDP) in the management of locally advanced or recurrent head and neck cancer (LARHNC).- Primary chemotherapy and surgery in advanced oral cavity squamous cell carcinomas: retrospective analysis.- Neo-Adjuvant intra-arterial chemotherapy by Cisplatin and 5-FU for squamous cell carcinoma of the oral cavity.- Treatment of locally advanced head and neck cancer with Neo-Adjuvant Cisplatin (CDDP) and 5-Fluorouracil (5-FU) chemotherapy (CT).- T3T4 operable cancer of oral cavity and oropharynx. Randomised trial for surgery and radiotherapy.- Neo-Adjuvant chemotherapy on T2 cancers in oropharyngeal and oral cavity.- Perioperative chemotherapy in hypopharyngeal squamous cell carcinomas.- Urology.- Chemotherapy for invasive bladder cancer: rationale and results.- Concomitant radiotherapy and Cisplatin in transitional cell bladder cancer.- Neo-Adjuvant chemotherapy for invasive transitional cell carcinoma (TCC) of the urinary bladder.- Neo-Adjuvant chemotherapy: Epirubicin in invasive bladder cancer; 4-year follow-up.- Preliminary results of a protocol of pre-operative radiation therapy with concomitant chemotherapy for invasive bladder cancer.- Induction chemotherapy with Methotrexate, Vinblastine, Epiadriamycin and Carboplatin (M-VEP) in transitional cell urothelial cancer.- Neo-Adjuvant chemotherapy aiming at bladder preservation.- Immunotherapy in metastatic renal cell cancer. The Lyon's experience on 100 patients.- Breast.- Induction chemotherapy prior to definitive treatment improves outcome in stage III carcinoma of the breast.- Multimodality treatment of stage II, III and IV breast cancer with biochemical modulation of 5-FU/Leucovorin and estrogen recruitment.- Ten years of breast preserving management in infiltrative breast cancer: results in 412 patients treated by Neo-Adjuvant chemotherapy and radiation therapy with or without hormonotherapy.- Results of Cisplatin (CPPD)/Etoposide (VP16)/5FU and alternatively Adriamycin or Mitomycin C (PEFAM) combination in primary resistant breast cancer and in heavily pre-treated metastatic breast cancer.- Primary chemotherapy for breast cancer - M.-D. Anderson experience.- Intensive and prolonged first line chemotherapy in breast cancer.- Surgical techniques for breast conserving surgery after pre-operative chemotherapy. The NSABP experience.- Neo-Adjuvant chemotherapy in 101 non inflammatory breast cancers: treatment results.- Flow cytometric DNA analysis and Samba computer assisted image analysis in the evaluation of breat carcinoma chemosensitivity.- Application of dose intensity to Neo-Adjuvant therapy.- Conservative management of breast cancer by exclusive radiation therapy following Neo-Adjuvant chemotherapy: results in 236 patients with a minimum 5 years follow-up.- Prognosis of breast cancer by state of the art laboratory techniques.- Histological and radio-clinical evaluation of locoregional response to primary chemotherapy in non inflammatory breast cancers.- Breast cancer cell kinetic as prognostic parameter in perioperative adjuvant chemotherapy.- Cytotoxic or endocrine primary systemic therapy (PST) for operable large primary breast cancer.- Early results of the British Columbia breast cancer preoperative (Neo-Adjuvant) chemotherapy trial.- Combined modality approach in treatment of inflammatory carcinoma of the breast - M.D. Anderson Cancer Center Experience.- Induction chemotherapy in locally advanced breast cancer: prognostic variables affecting results.- Dose response relationship with epirubicin in Neo-Adjuvant combination chemotherapy for advanced breast cancer. End results of a prospective randomized trial.- Continuous prolonged intra-arterial (IA) chemotherapy for extensive locally recurrent breast cancer.- Locoregional advanced breast cancer. Clinical response to Neo-Adjuvant chemotherapy and survival.- Gastro-Intestinal Tumors.- Clinical outcome of intraperitoneal hyperthermo-chemotherapy for patients with refractory gastric cancer.- Neo-Adjuvant therapy for gastric cancer.- The effects of Verapamil in potentiating the action of Doxorubicin in recently derived pancreatic carcinoma cell lines.- Preoperative 5-Fluorouracil in resectable colorectal cancer. Preliminary results of a prospective randomized trial.- Double 5-FU modulation with folinic acid and recombinant alfa 2b-Interferon: a phase I-II study in metastatic colorectal cancer patients.- Loco-Regional.- Neo-Adjuvant locoregional chemotherapy in pelvis osteosarcoma.- Treatment of advanced intra-abdominal or thoracic malignancies using high-dose intra-arterial chemotherapy with concomitant hemofiltration.- Technical aspects of adjuvant intraperitoneal chemotherapy.- Combined intravenous and intra-arterial chemotherapy using Cisplatin, Fluorouracil, Mitomycin C and Etoposide in the treatment of hepatic metastasis.- Drug sensitivity testing for regional chemotherapy.- Preoperative intra-arterial chemotherapy of advanced breast cancer. Response rate as prognostic factor for overall survival.- High dose of Rtnf? with interferon-g and melphalan in isolation perfusion (ILP) for in transit melanoma metastases and recurrent soft tissue sarcoma.- Testicular circulatory isolation prevents testicular exposure to doxorubicin in a rat model.- Early postoperative intraperitoneal Adriamycin.
|
|
|
:
|
Pharmacologic studies and a preliminary clinical report.- Surgical treatment of pseudomyxoma peritonei.- Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer.- Esophagus.- Neo-Adjuvant therapy for esophagus cancer: a coming of age.- Symptomatic improvement and esophagoscopic response after Neo-Adjuvant chemotherapy with Cisplatin, Vindesine and Bleomycin in patients with esophageal cancer (EC).- Non surgical multimodality treatment of squamous cell cancer of the esophagus.- Role of pathologic response after primary chemoradiotherapy and esophagectomy for predicted T3-4 NO-1 MO squamous carcinoma of the thoracic esophagus.- Gynecology.- Neo-Adjuvant chemotherapy in cervical cancer stage IIb; PEC + RT vs RT. Preliminary results.- Follow-up of treated gynecologic cancer: CT and MRI contribution.- Intra-arterial chemotherapy in uterine cancer.- Concomitant chemotherapy and radiotherapy in the treatment of advanced cervix carcinomas.- High-Dose Chemotherapy.- High-dose chemotherapy with hematologic rescue for high-risk nonseminomatous germ cell tumors.- High-dose chemotherapy and autologous bone marrow transplantation.- High-dose therapy in breast cancer.- Radio-Chemotherapy.- Differential expression of P-glycoprotein and certain other multidrug resistance characteristics in tumour cells pre-exposed in vitro either to anti-tumour drugs or to fractionated radiation.- Simultaneous chemo-radiotherapy in advanced head and neck cancer.- Pediatric Tumors.- Two different regimens with ifosfamide as preoperative chemotherapy in children with unresectable rhabdomyosarcoma. A report from the German soft tissue sarcoma study CWS-86 and the Italian rhabdomyosarcoma study ICG-88.- Limb sparing treatment in osteosarcoma with Neo-Adjuvant chemotherapy and intraoperative radiotherapy in pediatric patients. Analysis of local control.- Bone and Soft Tissue Sarcomas.- The combination of Etoposide and Cyclophosphamide as Neo-Adjuvant chemotherapy for osteosarcoma.- Dose response relationship in adult osteosarcoma patients treated with Neo-Adjuvant high dose Methotrexate, surgery and adjuvant chemotherapy.- Chemotherapy of soft tissue sarcomas with Cyclophosphamid or Ifosfamid, Adriamycin and DTIC (CAD or IAD) preoperatively and in patients with metastatic disease: a non randomized pilot study.- Phase II study of THP-adriamycin (Pirarubicin) and DTIC in advanced soft tissue sarcomas.- Combined approach to malignant small round blue cell neoplasms in the adult.- Neo-Adjuvant chemotherapy in the management of appendicular soft tissue sarcomas.- Hematosarcomas.- Neo-Adjuvant treatment in locally advanced thymoma.- Neo-Adjuvant chemotherapy in locally advanced invasive thymomas.- Neo-Adjuvant chemotherapy for invasive thymoma: an interim analysis.- Involvement of the Interleukin 2/Interleukin 2-receptor system in the proliferation of human immature leukemic T cells.- Pharmacokinetic.- Issues in multidrug resistance.- Pharmacokinetic study of Neo-Adjuvant chemotherapy combining Carboplatin, Cisplatin and 5-Fluorouracil in head and neck squamous cell carcinoma.- The influence of tumour stage on in vitro sensitivity of renal carcinoma cells to Mitozantrone.- Circadian chemotherapy against stage IIIB-IV non-small-cell lung cancer (NSCLC) with 5-Fluorouracil (5-FU), folinic acid (FOL) and cisplatin (CDDP) via a multichannel programmable pump. Preliminary results.- New Drugs.- Morpholinyl anthracyclines: option for reversal of anthracycline resistance ?.- Diarysulfonylureas: new anticancer agents with novel activities, toxicities and mechanism of action.- Current development of fotemustine: perspectives.- CPT-11: An analog of Camptothecin in early clinical development.- Modulation of glutathione and associated enzymes as a therapeutic strategy.- Lung.- Neo-Adjuvant chemotherapy (N-CT) followed by concomitant chemotherapy and radiotherapy (CC-CT) for locally advanced non-small cell lung cancer (NSCLC).- Multimodality therapy of non-small cell lung cancer (NSCLC).- Combined modality therapy for stage III non-small cell lung cancer: the University of Chicago experience.- High incidence of CNS metastases in long-term survivors (LTS) stage III (T4/N2) non-small Cell Lung Cancer (NSCLC). Patients treated with Neo-Adjuvant chemotherapy.- Combined modality therapy for stage IIIA (clinical N2) non-small cell carcinoma of the lung (NSCLC).- Phase II pilot study of Ifosfamide-Cisplatin-Etoposide association as Neo-Adjuvant chemotherapy in locally advanced non-small cell lung cancers.- Initial intensive drug chemotherapy (CT) followed by extensive irradiation for limited small cell lung cancer (LSCLC). Improved response rate and survival. A pilot study.- Cisplatinum, 5-Fluorouracil + Leucovorin and Vindesine, in non-small cell lung cancer: a phase II study.- Faster response and survival advantage with Neo-Adjuvant Cisplatin and 5-Fluorouracil infusion versus Cisplatin and Bleomycin in advanced non-small cell lung cancer.- Multimodality treatment for small cell bronchial carcinoma (SCLC).- Special Lectures.- Neo-Adjuvant chemotherapy: new approaches involving alkylating agent modulation.- The impact of molecular genetics on the detection of residual malignant disease.- Hairy cell leukemia: current treatment strategies.- Dose intensification and autologous stem cell support in breast cancer.- The current status of therapy for aggressive non-Hodgkin lymphoma.
|
| LC Classification
|
:
|
RC271.A35P763 2014
|
| |